Humana
HUM
$327.54
+2.08%
Humana Inc. is one of the largest private health insurers in the United States, operating within the Medical - Healthcare Plans industry. The company has carved out a distinct niche by specializing in government-sponsored programs, with nearly all its medical membership derived from Medicare, Medicaid, and the military's Tricare program, and it also provides complementary healthcare services like primary care and pharmacy benefit management. The current investor narrative is dominated by the sector-wide impact of favorable Medicare Advantage payment updates from CMS, which have significantly improved revenue visibility, though the stock has experienced dramatic volatility as the market debates the sustainability of this positive regulatory shift against underlying profitability challenges.…
HUM
Humana
$327.54
Related headlines
Investment Opinion: Should I buy HUM Today?
Rating & Thesis: Hold. Humana is a high-risk, high-reward turnaround story where a powerful regulatory catalyst has been priced in, but execution risk remains exceptionally high. The neutral analyst consensus and mixed ratings (from Sell to Buy) reflect this uncertain middle ground.
Supporting Evidence: The investment case rests on four data points: 1) The forward P/E of 19.6x implies a significant earnings recovery from the trailing P/E of 26x. 2) Revenue growth remains solid at 11.3% YoY. 3) The stock trades at a deep discount on a sales basis (P/S of 0.24). 4) The technical breakout toward the 52-week high suggests strong momentum. However, this is counterbalanced by severe profitability issues, including a Q4 gross margin of 11.67% and a TTM net margin of 0.92%, which are poor for the sector.
Risks & Conditions: The two biggest risks are a failure to stabilize quarterly earnings and a subsequent valuation derating. This Hold rating would upgrade to a Buy if the company demonstrates two consecutive quarters of expanding gross margins above 15% and consistent positive free cash flow generation. It would downgrade to a Sell if revenue growth decelerates below 5% YoY or if the forward P/E expands above 25x without corresponding margin improvement. Relative to its own chaotic history and current fundamentals, the stock appears fairly valued, pricing in a hopeful recovery but little room for error.
Sign up to view all
HUM 12-Month Price Forecast
The outlook is bifurcated between a powerful narrative-driven rally and persistently weak fundamentals. The recent CMS catalyst is real and significant, justifying a portion of the rally, but the stock now trades at a level that requires proof of sustained margin improvement. The base case of choppy, range-bound trading is most likely, as the market awaits concrete evidence that profitability has turned a corner. The stance would upgrade to bullish on confirmation of two consecutive quarters of margin expansion and operating cash flow positivity. It would turn bearish if the next earnings report shows another gross margin collapse below 12%.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Humana's 12-month outlook, with a consensus price target around $425.80 and implied upside of +30.0% versus the current price.
Average Target
$425.80
7 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
7
covering this stock
Price Range
$262 - $426
Analyst target range
Analyst coverage for Humana appears limited with only 7 analysts providing estimates, and the institutional ratings data shows a recent flurry of activity centered around February 2026, primarily reiterating Hold or Neutral stances. The consensus sentiment is neutral to cautious, with recent actions from major firms including Barclays and Wells Fargo maintaining 'Equal Weight', Goldman Sachs maintaining 'Sell', and Jefferies and Guggenheim maintaining 'Buy' ratings. The average target price is not explicitly provided in the data, but analyst estimates point to an average EPS forecast of $41.26 on average revenue of $207.23 billion for the forward period. The wide range between the low EPS estimate of $39.44 and the high of $44.18 signals significant uncertainty and divergence in views on the company's earnings power post-catalyst. This limited coverage and mixed, recently static ratings suggest that while a major negative overhang (Medicare rates) has been alleviated, analysts remain watchful for evidence of sustained execution and margin improvement before turning more uniformly bullish.
Bulls vs Bears: HUM Investment Factors
The bull case, centered on a transformative regulatory catalyst and strong price momentum, currently holds stronger evidence, as reflected in the stock's 60% three-month rally. However, the bear case presents a formidable counter-argument grounded in the company's demonstrably volatile and weak profitability fundamentals. The single most important tension in the investment debate is whether the improved Medicare payment environment will be sufficient to stabilize Humana's erratic quarterly earnings and translate into sustained, high-quality profitability, or if underlying medical cost trends and operational inefficiencies will continue to pressure margins, rendering the recent rally unsustainable.
Bullish
- Powerful Regulatory Catalyst: The stock's 60% surge in 3 months is driven by a favorable Medicare Advantage payment update from CMS, which analysts estimate adds $13 billion in sector revenue and significantly improves forward revenue visibility. This positive regulatory shift has fundamentally altered the near-term outlook for Humana's core business.
- Strong Revenue Growth Trajectory: Q4 2025 revenue grew 11.3% year-over-year to $32.52 billion, demonstrating robust top-line expansion. The forward revenue estimate of $207.23 billion suggests the market expects continued growth, supported by the company's specialization in government-sponsored healthcare programs.
- Attractive Forward Valuation: The forward P/E of 19.61x represents a significant discount to the trailing P/E of 25.97x, indicating the market is pricing in a substantial earnings recovery. The low Price-to-Sales ratio of 0.24 also suggests the stock is not expensive on a sales basis relative to its history.
- Positive Technical Momentum: The stock has exhibited exceptional relative strength, gaining 25.63% over the past month versus the S&P 500's 6.31%, and is now testing its 52-week high of $315.66. A confirmed breakout above this level would signal a resumption of the long-term uptrend.
Bearish
- Extreme Profitability Volatility: The company swung from a Q1 2025 net income of $1.24 billion to a Q4 2025 net loss of -$796 million, with gross margins collapsing from 17.37% to 11.67%. This severe quarterly volatility and a TTM net margin of just 0.92% highlight persistent operational challenges and medical cost pressures.
- Valuation Disconnect with Fundamentals: Despite recent losses, the stock trades at a trailing P/E of 25.97x, which is a premium valuation demanding flawless execution. The negative PEG ratio of -18.57 signals the market is paying a high price for earnings that are not growing in a stable manner.
- Cash Flow and Liquidity Concerns: Quarterly cash flow is highly volatile, with Q4 2025 showing an operating cash flow deficit of -$1.65 billion. While TTM free cash flow is positive at $375 million, this inconsistency, coupled with a current ratio of 0.72, raises questions about financial flexibility.
- Analyst Skepticism and High Uncertainty: Analyst coverage is limited (7 analysts) and sentiment is mixed, with recent reiterations of Hold, Neutral, and even Sell ratings. The wide EPS estimate range ($39.44 to $44.18) reflects significant divergence and uncertainty about the company's ability to capitalize on the regulatory catalyst.
HUM Technical Analysis
The stock is in a powerful recovery trend, having surged 60.29% over the past three months, dramatically reversing a severe downtrend that saw the price plummet from a high near $283 in mid-January to a 52-week low of $163.11 in March. Currently trading at $305.42, the price sits at approximately 96.5% of its 52-week range ($163.11 to $315.66), indicating it is testing major resistance at the upper bounds of its yearly range, a level that could signal either a decisive breakout or a point of exhaustion after the sharp rally. Recent momentum is exceptionally strong, with a 25.63% gain over the past month, which significantly outpaces the S&P 500's 6.31% gain, as evidenced by a relative strength reading of 19.32; this acceleration from the longer-term 1-year gain of 32.75% suggests a powerful short-term catalyst is driving the stock, likely the positive Medicare news, but also raises the risk of a sharp pullback if momentum falters. Key technical support is now anchored at the March low of $163.11, while immediate resistance is the 52-week high of $315.66; a confirmed breakout above $315.66 would signal a resumption of the long-term uptrend, whereas a failure here could lead to consolidation. The stock's beta of 0.683 indicates it has been less volatile than the broader market historically, but the recent price action—including a maximum drawdown of -47.54%—demonstrates that it can exhibit extreme volatility around specific events, requiring careful risk management despite its lower beta.
Beta
0.68
0.68x market volatility
Max Drawdown
-47.5%
Largest decline past year
52-Week Range
$163-$333
Price range past year
Annual Return
+40.3%
Cumulative gain past year
| Period | HUM Return | S&P 500 |
|---|---|---|
| 1m | +37.6% | +5.0% |
| 3m | +81.2% | +10.7% |
| 6m | +27.0% | +10.0% |
| 1y | +40.3% | +26.5% |
| ytd | +23.8% | +10.6% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
HUM Fundamental Analysis
Revenue growth remains robust, with Q4 2025 revenue of $32.52 billion representing an 11.3% year-over-year increase; however, this growth masks severe quarterly volatility in profitability, as revenue actually declined slightly from Q3's $32.65 billion. The Insurance Segment, generating $31.34 billion, is the dominant driver, while the CenterWell Segment contributed $5.96 billion, indicating the company's integrated care model. Profitability has been highly inconsistent, with the company swinging from a net income of $1.24 billion and a gross margin of 17.37% in Q1 2025 to a net loss of $796 million and a gross margin of just 11.67% in Q4 2025; this compression highlights significant margin pressure and operational challenges within its core insurance business, particularly around medical cost trends. The trailing twelve-month net margin is a thin 0.92%, and operating margin is 1.12%, which are low for the managed care sector and underscore the profitability headwinds the company faces. The balance sheet shows moderate leverage with a debt-to-equity ratio of 0.73, and liquidity is adequate with a current ratio of 0.72. Critically, free cash flow over the trailing twelve months is a positive $375 million, but quarterly cash flow is highly volatile, with Q4 2025 showing an operating cash flow deficit of -$1.65 billion; this variability suggests the company's ability to internally fund growth or return capital is inconsistent and highly sensitive to quarterly earnings performance and working capital movements.
Quarterly Revenue
$32.5B
2025-12
Revenue YoY Growth
+0.11%
YoY Comparison
Gross Margin
+0.11%
Latest Quarter
Free Cash Flow
$375000000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is HUM Overvalued?
Given the company's positive trailing twelve-month net income, the primary valuation metric is the Price-to-Earnings (PE) ratio. Humana trades at a trailing PE of 25.97x, which is significantly higher than its forward PE of 19.61x; this gap implies the market expects a significant recovery in earnings over the next twelve months, aligning with the improved guidance following the Medicare payment update. Compared to sector averages implied by its own historical data, the current trailing PE of 25.97x is below the elevated multiples seen in 2021-2023 (which often exceeded 30x) but represents a substantial premium to the deeply negative PE ratios recorded during recent loss-making quarters like Q4 2025 (-9.68x). The stock's Price-to-Sales ratio of 0.24 and EV-to-Sales of 0.22 appear low on an absolute basis, suggesting the market is applying a discount on sales due to the aforementioned thin and volatile profitability. Historically, the stock's own trailing PE has swung wildly from over 1,000x during negligible profit periods to as low as 6.4x during high-profit quarters, placing the current 25.97x near the middle of its own chaotic range; this indicates the market is pricing in a normalization of earnings, but the stock remains sensitive to any deviation from these recovering profit expectations.
PE
26.0x
Latest Quarter
vs. Historical
High-End
5-Year PE Range -1073x~40x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
13.6x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks: Humana's primary risk is its extreme earnings volatility, as evidenced by the swing from a $1.24 billion profit in Q1 2025 to a $796 million loss in Q4 2025. This is compounded by thin margins, with a trailing operating margin of just 1.12%, and inconsistent cash generation, highlighted by a -$1.65 billion operating cash flow in the latest quarter. The company's heavy reliance on government reimbursement programs (Medicare/Medicaid) creates revenue concentration risk, making it highly sensitive to regulatory changes and medical cost trends that it cannot fully control.
Market & Competitive Risks: The stock's valuation presents a key market risk. At a forward P/E of 19.6x, it trades at a premium that demands perfect execution and margin recovery. Any disappointment in quarterly earnings could trigger significant multiple compression, as seen in the stock's history of wild P/E swings. Competitive pressure within the managed care sector is intense, and while the recent CMS news benefited the entire group, Humana's low profitability metrics (0.92% net margin) leave it vulnerable if it cannot keep pace with more efficient peers. The stock's beta of 0.68 suggests lower systematic risk, but its 47.54% maximum drawdown proves it carries significant idiosyncratic, event-driven volatility.
Worst-Case Scenario: The worst-case scenario involves a failure to capitalize on the improved Medicare landscape, coupled with a resurgence of unfavorable medical cost trends. This could lead to another steep earnings miss, triggering analyst downgrades and a rapid derating of the forward P/E multiple. A re-test of the March 2026 low of $163.11 is plausible, which would represent a downside of approximately -47% from the current price of $305.42. This scenario would likely be catalyzed by a Q3 or Q4 2026 earnings report that shows continued margin pressure despite the revenue tailwind.
FAQ
The key risks are, in order of severity: 1) Profitability Risk: Extreme quarterly earnings volatility and compressed margins (Q4 gross margin of 11.67%) could persist, invalidating the recovery thesis. 2) Execution Risk: The company may fail to translate the Medicare payment boost into sustained profit growth, leading to multiple compression. 3) Valuation Risk: At a forward P/E of 19.6x, any earnings disappointment could trigger a sharp decline, as seen in the stock's 47.54% maximum drawdown. 4) Regulatory & Competitive Risk: Future changes to Medicare/Medicaid reimbursement and intense sector competition could pressure the core business model despite the recent positive news.
The 12-month forecast is highly uncertain, centered on three scenarios. The base case (50% probability) sees the stock trading between $300 and $340 as the company shows gradual, uneven progress on margins. The bull case (30% probability), targeting $340-$380, requires flawless execution and margin expansion, beating high-end EPS estimates. The bear case (20% probability), targeting $180-$240, involves another earnings miss and a derating of the multiple. The most likely outcome is the base case, as it incorporates the positive regulatory catalyst but acknowledges the company's history of operational volatility. The average analyst EPS estimate for the forward period is $41.26.
HUM is fairly valued relative to its improved outlook but carries a premium relative to its unstable fundamentals. The forward P/E of 19.6x is reasonable if the company hits its average EPS target of $41.26, representing a significant earnings recovery. The low Price-to-Sales ratio of 0.24 suggests the market is not overpaying for revenue. However, the valuation is precarious; the stock trades at a premium that assumes a successful turnaround. Given the history of wild P/E swings and recent losses, the current multiple leaves little margin for error, implying the market is paying for expected future performance that is far from guaranteed.
HUM is a high-risk, event-driven investment rather than a straightforward 'good buy.' For investors with a high risk tolerance and a belief that management can stabilize margins, the recent 60% rally on positive Medicare news may have further legs, with analyst EPS targets implying significant earnings growth. However, the stock's extreme quarterly volatility—swinging from a $1.24B profit to a $796M loss within a year—and thin net margin of 0.92% present substantial execution risk. It could be a good buy for speculative portfolios seeking regulatory catalyst plays, but is unsuitable for conservative investors seeking stability and consistent earnings.
HUM is primarily suitable for medium-term tactical investing (6-18 months) rather than long-term buy-and-hold. The investment thesis is currently driven by a specific regulatory catalyst and the subsequent earnings recovery narrative, which will be proven or disproven over the next few quarters. The stock's high volatility (47.54% max drawdown) and lack of a consistent earnings profile make it a poor fit for long-term, low-risk portfolios. Short-term traders can capitalize on momentum swings, but the low beta of 0.68 is misleading given its event-driven price action. A minimum holding period through at least the next two earnings reports is advised to assess the turnaround's validity.